SCHEMBL480668

SCHEMBL480668

CC(C)(C)CC(C)(C)c1ccc(Oc2ccc(C(C)(C)CC(C)(C)C)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
SHBG P04278 1/20 0.59
MAPT P10636 4/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
ALDH1A1 P00352 3/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
MDH1 P40925 6/20 0.44
MDH2 P40926 6/20 0.44
HIF1A Q16665 3/20 0.42
MEN1 O00255 2/20 0.42
APAF1 O14727 2/20 0.42
USP2 O75604 2/20 0.42
LMNA P02545 2/20 0.42
ERBB2 P04626 2/20 0.42
TP53 P04637 2/20 0.42
FYN P06241 2/20 0.42
CHRM2 P08172 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10435899 0.92 CYP3A4 (0.54) CYP3A4SMN1; SMN2SHBGMAPTNPC1
Ethylene Glycol SCHEMBL1832016 0.92 CYP3A4 (0.69) CYP3A4SMN1; SMN2SHBGMAPTNPC1
SCHEMBL4672138 0.90 MAPT (0.71) CYP3A4SMN1; SMN2SHBGMAPTNPC1
Oxirane SCHEMBL28748999 0.90 CYP3A4 (0.53) CYP3A4SMN1; SMN2SHBGMAPTNPC1
1,4-Butanediol SCHEMBL1592411 0.89 CYP3A4 (0.65) CYP3A4SMN1; SMN2SHBGMAPTNPC1
SCHEMBL28747587 0.86 CYP3A4 (0.61) CYP3A4SMN1; SMN2SHBGMAPTNPC1
SCHEMBL3316442 0.86 CYP3A4 (0.49) CYP3A4SMN1; SMN2SHBGMAPTNPC1
SCHEMBL28472882 0.85 CYP3A4 (0.61) CYP3A4SMN1; SMN2SHBGMAPTNPC1
SCHEMBL7166618 0.84 CYP3A4 (0.59) CYP3A4SMN1; SMN2SHBGMAPTALDH1A1
SCHEMBL4672134 0.83 PARP10 (0.59) CYP3A4SMN1; SMN2SHBGMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570691-B2 Purification of chimeric FVIII molecules BIOVERATIV THERAPEUTICS INC. (US) 2026-03-10 US claimed
EP-4683955-A1 ANTI-FOG COATINGS AND METHOD OF USING THE SAME Actnano, Inc. (US) 2026-01-28 EP claimed
US-20260016466-A1 TEST PIECE FOR MEASURING ALBUMIN AND METHOD FOR MEASURING ALBUMIN FUJIFILM CORPORATION (JP) 2026-01-15 US claimed
WO-2025238653-A1 MULTI-LAYER COATING FOR PHOTOVOLTAIC GLASS BOROSIL RENEWABLES LIMITED (IN) 2025-11-20 WO claimed
WO-2025226754-A1 METHOD FOR PREDICTING OSMOLALITY OF PROTEIN SOLUTIONS AMGEN INC. (US) 2025-10-30 WO claimed
EP-4638789-A1 METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES 10X Genomics, Inc. (US) 2025-10-29 EP claimed
EP-3315968-B1 UNIVERSAL ANTIGEN RETRIEVAL COMPOUNDS AND METHODS OF USE UNIV HOUSTON SYSTEM (US) 2025-10-15 EP claimed
US-20250297241-A1 LYSIS BUFFERS FOR EXTRACTING NUCLEIC ACIDS Life Technologies Corporation 2025-09-25 US claimed
EP-3906982-B2 PLASMA CLEANING METHOD WITH SIMULTANEOUS DEPLETION OF ENDOTOXINS AXAGARIUS GMBH & CO KG (DE) 2025-08-13 EP claimed
CN-120158761-A Preparation method and application of ultra-thin ultra-low noble metal integrated membrane electrode for inhibiting hydrogen permeation 大连理工大学 2025-06-17 CN claimed
EP-1533325-A1 Aqueous dispersions of polytetrafluoroethylene having a low amount of fluorinated surfactant 3M Innovative Properties Company (US) 2005-05-25 EP claimed
US-20050107518-A1 Aqueous dispersions of polytetrafluoroethylene having a low amount of fluorinated surfactant 3M INNOVATIVE PROPERTIES COMPANY 2005-05-19 US claimed
US-6207098-B1 Method for producing porous inorganic materials MERCK PATENT GMBH (DE) 2001-03-27 US claimed
US-5965389-A YEAST WHICH IS TRANSFORMED WITH DNA CONSTRUCT OF REGULATORY SEQUENCES AND DNA SEQUENCE CODING GLUTAMATE DECARBOXYLASE ISOFORM; FOR HIGH LEVEL GENE EXPRESSION AND INDUSTRIAL PRODUCTION OF ENZYME FOR SCREENING AND MONITORING OF DIABETES ZYMOGENETICS, INC. (US) 1999-10-12 US claimed
EP-0862640-A2 PRODUCTION OF GAD65 IN METHYLOTROPHIC YEAST ZymoGenetics, Inc. (US) 1998-09-09 EP claimed
WO-1997017451-A2 PRODUCTION OF GAD65 IN METHYLOTROPHIC YEAST ZYMOGENETICS, INC. (US) 1997-05-15 WO claimed
US-4892816-A CHOLESTEROL DEHYDROGENASE AND NAD OR NADP AMANO PHARMACEUTICAL CO., LTD. (JP) 1990-01-09 US claimed
EP-0183381-B1 METHOD FOR THE DETERMINATION OF CHOLESTEROL AMANO PHARMACEUTICAL CO., LTD. (JP) 1988-09-21 EP claimed
EP-0183381-A1 Method for the determination of cholesterol AMANO PHARMACEUTICAL CO., LTD. (JP) 1986-06-04 EP claimed
US-4289649-A LIPID-SOLUBILIZING AMOUNT OF BOTH A NONIONIC DETERGENT AND AN IONIC DETERGENT MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1981-09-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260016466-A1 TEST PIECE FOR MEASURING ALBUMIN AND METHOD FOR MEASURING ALBUMIN ALB, S100P, MB CYP3A4 4318/4885SMN1; SMN2 3164/4885SHBG 23/4885
US-12570691-B2 Purification of chimeric FVIII molecules F8, F9, F5 CYP3A4 4101/4885SMN1; SMN2 3532/4885SHBG 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.